Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer

Cellular and Molecular Biology Letters

Volumn 17, Issue 3, 2012, Pages 446-458

  Ruckova, Eva ^a   Muller, Petr ^a   Nenutil, Rudolf ^a   Vojtesek, Borivoj ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

17AAG; Cancer; Chaperone; CHIP; Co chaperone; HOP; HSF1; Hsp70; Hsp90

Indexed keywords

C TERMINUS OF HSC70 INTERACTING PROTEIN; CHAPERONE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; HSP70 HSP90 ORGANIZING PROTEIN; MESSENGER RNA; TANESPIMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME; UPREGULATION;

EID: 84863562310     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-012-0021-8     Document Type: Article

References (19)

1. Ciocca, D. R. and Calderwood, S. K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones10 (2005) 86-103.
2. Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 10 (2004) 47-51.
3. Hernandez, M. P., Sullivan, W. P. and Toft, D. O. The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J. Biol. Chem. 277 (2002) 38294-38304.
4. Kubota, H., Yamamoto, S., Itoh, E., Abe, Y., Nakamura, A., Izumi, Y., Okada, H., Iida, M., Nanjo, H., Itoh, H. and Yamamoto, Y. Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones15 (2010) 1003-1011.
5. Sun, W., Xing, B., Sun, Y., Du, X., Lu, M., Hao, C., Lu, Z., Mi, W., Wu, S., Wei, H., Gao, X., Zhu, Y., Jiang, Y., Qian, X. and He, F. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell. Proteomics6 (2007) 1798-1808.
6. Erlich, R. B., Kahn, S. A., Lima, F. R., Muras, A. G., Martins, R. A., Linden, R., Chiarini, L. B., Martins, V. R. and Moura Neto, V. STI1 promotes glioma proliferation through MAPK and PI3K pathways. Glia55 (2007) 1690-1698.
7. Kajiro, M., Hirota, R., Nakajima, Y., Kawanowa, K., So-ma, K., Ito, I., Yamaguchi, Y., Ohie, S. H., Kobayashi, Y., Seino, Y., Kawano, M., Kawabe, Y., Takei, H., Hayashi, S., Kurosumi, M., Murayama, A., Kimura, K. and Yanagisawa, J. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat. Cell. Biol. 11 (2009) 312-319.
8. Kundrat, L. and Regan, L. Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP. Biochemistry49 (2010) 7428-7438.
9. Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U. and Moarefi, I. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell101 (2000) 199-210.
10. Muller, P., Hrstka, R., Coomber, D., Lane, D. P. and Vojtesek, B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene27 (2008) 3371-3383.
11. Banks, L., Matlashewski, G. and Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159 (1986) 529-534.
12. Trepel, J., Mollapour, M., Giaccone, G. and Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer10 (2010) 537-549.
13. Pick, E., Kluger, Y., Giltnane, J. M., Moeder, C., Camp, R. L., Rimm, D. L. and Kluger, H. M. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 67 (2007) 2932-2937.
14. Li, C. F., Huang, W. W., Wu, J. M., Yu, S. C., Hu, T. H., Uen, Y. H., Tian, Y. F., Lin, C. N., Lu, D., Fang, F. M. and Huang, H. Y. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin. Cancer Res. 14 (2008) 7822-7831.
15. Kang, G. H., Lee, E. J., Jang, K. T., Kim, K. M., Park, C. K., Lee, C. S., Kang, D. Y., Lee, S. H., Sohn, T. S. and Kim, S. Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours. Histopathology56 (2010) 694-701.
16. Stankiewicz, M., Nikolay, R., Rybin, V. and Mayer, M. P. CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates. FEBS J. 277 (2010) 3353-3367.
17. Santagata, S., Hu, R., Lin, N. U., Mendillo, M. L., Collins, L. C., Hankinson, S. E., Schnitt, S. J., Whitesell, L., Tamimi, R. M., Lindquist, S. and Ince, T. A. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc. Natl. Acad. Sci. USA108 (2011) 18378-18383.
18. Dai, C., Whitesell, L., Rogers, A. B. and Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell130 (2007) 1005-1018.
19. Zou, J., Guo, Y., Guettouche, T., Smith, D. F. and Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell94 (1998) 471-480.